scholarly journals REDUCED PROGRESSION OF ATRIAL FIBRILLATION IN HYPERTENSIVE PATIENTS WITH LONG-TERM TREATMENT OF PROPAFENONE

2019 ◽  
Vol 37 ◽  
pp. e182
Author(s):  
V. Podzolkov ◽  
A. Tarzimanova ◽  
R. Gataulin
1988 ◽  
Vol 6 (11) ◽  
pp. 925-930 ◽  
Author(s):  
Antoon Amery ◽  
Willem Birkenh??ger ◽  
Christopher Bulpitt ◽  
Denis Clement ◽  
Peter de Leeuw ◽  
...  

2015 ◽  
Vol 28 (4) ◽  
pp. 269-272
Author(s):  
Anna Szczepańska-Szerej ◽  
Magdalena Wojtan ◽  
Beata Szajnoga

Abstract It is estimated that nearly 20% of all cerebral infarctions in the total population are the result of a complication of atrial fibrillation (AF). While oral anticoagulation with vitamin K antagonists (AVKs) substantially reduces this risk, this requires regular monitoring of the international normalized ratio (INR) in order to achieve therapeutic levels (2,0-3,0). The aim of this study was to evaluate a group at high risk of cerebral infarction, among patients with AF undergoing long-term treatment with VKAs, taking into account the significance of therapeutic INR values. The analysed group consisted of 90 acute ischaemic stroke patients with paroxysmal or chronic “non-valvular” AF, receiving treatment with VKAs. As a result of the study, therapeutic INR values (≥ 2) were seen in thirty-five of these individuals (38,8%), while 55 (61,2%) showed non-therapeutic INR values. Moreover, there were no differences in demographics, vascular risk factors, biochemical and morphological blood parameters, mean CHA2DS2-VASc score and TOAST classification between either of the two groups. Furthermore, no additional factor that would increase their risk of cerebral infarction during the adequate treatment with VKAs was found. However, patients with non-therapeutic INR values had a statistically significantly higher frequency of concomitant moderate pathology of the bicuspid valve, p<0.05. Hence, a lack of proper control of INR can proved to be particularly dangerous for this subgroup of patients. Hence, this is a group with an elevated risk of cerebral infarction and therefore requires special oversight of VKA treatment or NOA treatment.


2005 ◽  
Vol 26 (13) ◽  
pp. 1303-1308 ◽  
Author(s):  
Karl Swedberg ◽  
Lars G. Olsson ◽  
Andrew Charlesworth ◽  
John Cleland ◽  
Peter Hanrath ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document